June 7, 2005Journal of Hypertension

Co-administration of lower doses of azelnidipine (0.1 mg/kg a day) and olmesartan (1 mg/kg a day) significantly inhibited the atherosclerotic area and oxidative stress, whereas azelnidipine or olmesartan alone at these doses did not affect these parameters.

View Full Paper

Ask AI

Bookmark

Why the study?

Does the co-administration of azelnidipine and olmesartan prevent atherosclerosis in apolipoprotein E-deficient mice?

Population

Apolipoprotein E-deficient mice maintained on a 1.25% high-cholesterol diet for 10 weeks, and cultured…

Comparison

Co-administration of azelnidipine and olmesartan vs Azelnidipine alone or olmesartan alone

Design

Preclinical

Follow-up

10 weeks

Authors

JSJun Suzuki MIMasaru Iwai ZLZhen Li

Discussion

Member takes

Overview

Supports synergistic anti-atherosclerotic effects of low-dose combination in mice; hypothesis-generating and requires clinical validation before human use.

Structured PICO

Does the co-administration of azelnidipine and olmesartan prevent atherosclerosis in apolipoprotein E-deficient mice?

Population

Apolipoprotein E-deficient mice maintained on a 1.25% high-cholesterol diet for 10 weeks, and cultured vascular smooth muscle cells

Intervention

Co-administration of azelnidipine (0.1 mg/kg a day) and olmesartan (1 mg/kg a day)

Comparator

Azelnidipine alone (0.1 mg/kg a day) or olmesartan alone (1 mg/kg a day)

Outcome

Atherosclerotic area and oxidative stress (expression of NAD(P)H oxidase subunits p22 and p47, and superoxide anion production)surrogate

The combination of a calcium antagonist and an ARB synergistically blunts oxidative stress and enhances anti-atherosclerotic effects compared to monotherapy in a mouse model.

Cite This Study

Suzuki et al. (2005) studied this question.

synapsesocial.com/papers/6a70fcbb35aa2c282ce24f7d https://doi.org/10.1097/01.hjh.0000173521.91104.5f

View Full Paper

Ask AI

Bookmark

June 7, 2005Journal of Hypertension

Co-administration of lower doses of azelnidipine (0.1 mg/kg a day) and olmesartan (1 mg/kg a day) significantly inhibited the atherosclerotic area and oxidative stress, whereas azelnidipine or olmesartan alone at these doses did not affect these parameters.

View Full Paper

Ask AI

Bookmark

Why the study?

Does the co-administration of azelnidipine and olmesartan prevent atherosclerosis in apolipoprotein E-deficient mice?

Population

Apolipoprotein E-deficient mice maintained on a 1.25% high-cholesterol diet for 10 weeks, and cultured…

Comparison

Co-administration of azelnidipine and olmesartan vs Azelnidipine alone or olmesartan alone

Design

Preclinical

Follow-up

10 weeks

Authors

JSJun Suzuki MIMasaru Iwai ZLZhen Li

Discussion

Member takes

Overview

Supports synergistic anti-atherosclerotic effects of low-dose combination in mice; hypothesis-generating and requires clinical validation before human use.

Structured PICO

Does the co-administration of azelnidipine and olmesartan prevent atherosclerosis in apolipoprotein E-deficient mice?

Population

Apolipoprotein E-deficient mice maintained on a 1.25% high-cholesterol diet for 10 weeks, and cultured vascular smooth muscle cells

Intervention

Co-administration of azelnidipine (0.1 mg/kg a day) and olmesartan (1 mg/kg a day)

Comparator

Azelnidipine alone (0.1 mg/kg a day) or olmesartan alone (1 mg/kg a day)

Outcome

Atherosclerotic area and oxidative stress (expression of NAD(P)H oxidase subunits p22 and p47, and superoxide anion production)surrogate

The combination of a calcium antagonist and an ARB synergistically blunts oxidative stress and enhances anti-atherosclerotic effects compared to monotherapy in a mouse model.

Cite This Study

Suzuki et al. (2005) studied this question.

synapsesocial.com/papers/6a70fcbb35aa2c282ce24f7d https://doi.org/10.1097/01.hjh.0000173521.91104.5f

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark